₹-0.06
(Market cap
₹66 Cr
Revenue (TTM)
₹140 Cr
P/E Ratio
41.1
P/B Ratio
1
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹1 Cr
-
ROE
1.9 %
-
ROCE
3.4 %
-
Industry P/E
24.24
-
EV/EBITDA
20.3
-
Debt to Equity
0.4
-
Book Value
₹1.2
-
EPS
₹0
-
Face value
1
-
Shares outstanding
553,719,700
10 Years Aggregate
CFO
₹-12.31 Cr
EBITDA
₹1.42 Cr
Net Profit
₹4.64 Cr
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Genpharmasec
| -9.2 | -8.5 | 0.8 | -45.4 | -14.7 | -25.3 | -9.4 |
|
BSE Commodities
| 8.9 | 1.7 | 5.1 | 14.8 | 17.9 | 11.5 | 16.2 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Genpharmasec
| -61.0 | 7.8 | 12.8 | -21.1 | -51.6 | -18.0 | -1.0 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Commodities
| 12.5 | 8.1 | 17.5 | 1.2 | 61.5 | 26.1 | -4.6 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Genpharmasec
|
1.2 | 65.9 | 139.9 | 0.6 | -0.7 | 1.3 | 41.1 | 1.0 |
| 1,651.3 | 8,456.7 | 1,535.9 | 180.0 | 13.9 | 12.1 | 47 | 5.5 | |
| 3,399.7 | 14,775.1 | 15,226.8 | 420.1 | 3.4 | 10.7 | 35.2 | 3.7 | |
| 1,410.1 | 17,872.1 | 11,506.0 | 738.8 | 11.0 | 11 | 24.2 | 2.4 | |
| 1,160.9 | 5,021.0 | 2,527.2 | 332.0 | 15.8 | 16.1 | 15.1 | 2.3 | |
| 1,795.3 | 6,333.3 | 5,248.3 | 267.4 | 6.7 | 10.5 | 23.7 | 2.3 | |
| 2,640.8 | 8,496.9 | 15,929.8 | 1,844.4 | 16.6 | 12.4 | 9.1 | 1.1 | |
| 5,473.4 | 7,391.1 | 1,995.6 | 185.3 | 11.7 | 13.8 | 39.9 | 5.5 | |
| 7,129.0 | 36,254.1 | 3,313.9 | 663.6 | 28.1 | 17.7 | 54.6 | 9.1 | |
| 758.0 | 19,315.6 | 14,584.0 | -1,882.0 | 4.1 | 0.6 | -- | 0.9 |
Shareholding Pattern
View DetailsNews & Analysis
All NewsNo Review & Analysis are available.
About Genpharmasec
Adi Rasayan Limited engages in the trading of various goods and merchandise in India. It trades and deals in chemicals. The company was incorporated in 1992 and is based in Ahmedabad, India.
-
Incorporated
1992
-
Chairman
--
-
Managing Director
--
-
Headquarters
Mumbai, Maharashtra
-
Website
Looking for more details about Genpharmasec Ltd.’s IPO? Explore our IPO Details page.
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
FAQs for Genpharmasec
What is the current share price of Genpharmasec Ltd Today?
The share price of Genpharmasec Ltd is ₹1.19 (BSE) as of 29-May-2026 IST. Genpharmasec Ltd has given a return of -14.67% in the last 3 years.
What is the current PB & PE ratio of Genpharmasec Ltd?
The P/E ratio of Genpharmasec Ltd is 41.11 times as on 29-May-2026, a 70 premium to its peers’ median range of 24.24 times.
The P/B ratio of Genpharmasec Ltd is 0.99 times as on 29-May-2026, a 42 discount to its peers’ median range of 1.70 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
83.26
|
1.61
|
|
2024
|
0.00
|
1.92
|
|
2023
|
46.00
|
5.62
|
|
2022
|
0.00
|
9.91
|
|
2021
|
138.15
|
11.85
|
What is the 52 Week High and Low of Genpharmasec Ltd?
The 52-week high and low of Genpharmasec Ltd are Rs 2.33 and Rs 0.75 as of 01-Jun-2026.
What is the market cap of Genpharmasec Ltd?
Genpharmasec Ltd has a market capitalisation of ₹ 66 Cr as on 29-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Genpharmasec Ltd?
Before investing in Genpharmasec Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.